logo-loader
viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals receives new US patent for treatment of Fragile X syndrome with CBD

The new patent which expires in 2038, is part of an expanding intellectual property portfolio covering Zynerba’s flagship ZYN002 synthetic CBD gel

A marijuana plant and stethoscope
Zynerba is working on designing cannabis-derived treatments that can help patients suffering rare epilepsies and neurological disorders

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Tuesday that the US Patent and Trademark Office has issued a new patent to the company for its transdermal cannabinoid treatment for patients suffering Fragile X syndrome, the most common form of inherited learning disability and attention deficit disorder.

Interestingly, the company’s flagship product ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

The newly granted US patent No 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol,” includes claims directed at methods of treating Fragile X syndrome by administering “a therapeutically effective amount of synthetic or purified cannabidiol.”

Shares jumped nearly 17% to $5.88 in pre-market trading on heavy volume.

READ: Zynerba Pharmaceuticals’ quest for CBD gel to treat Fragile X syndrome ventures where big pharma fears to tread

The new patent which expires in 2038, is part of an expanding intellectual property portfolio covering the company's ZYN002 CBD gel.

The new patent comes at an auspicious time as enrollment speeds up in the CONNECT-FX clinical trial, which is a pivotal, multinational, randomized, double blind, placebo-controlled study evaluating the potential and safety of ZYN002.

Clinical investigative sites are enrolling patients in the United States, Australia, and New Zealand. Patients who have completed the double-blind phase are now enrolling into the 12-month open label phase.

The Devon, Pennsylvania-based Zynerba is on track to reporting topline results from the tests of its cannabidiol gel treatment for children and adolescents, aged three to 17, with Fragile X syndrome the second half of 2019.

Fragile X is also the most commonly known single gene cause of autism spectrum disorder.  

The company could be filing a New Drug Application for ZYN002 in the first half of 2020 for Fragile X Syndrome.

Zynerba is working on designing cannabis-derived treatments that can help patients suffering from rare epilepsies and neurological disorders.

--ADDS share price--

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Zynerba Pharmaceuticals

Price: 5.74 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $133.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read